Research programme: brain injury therapeutics - Chiesi

Drug Profile

Research programme: brain injury therapeutics - Chiesi

Latest Information Update: 15 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi
  • Class
  • Mechanism of Action Caspase inhibitors; Melatonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Brain injuries

Most Recent Events

  • 13 Jan 2016 Early research in Brain injuries (In neonates) in Italy (unspecified route) prior to January 2016 (Chiesi pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top